Targeting apoptosis to treat multiple sclerosis

Curr Drug Discov Technol. 2008 Mar;5(1):75-7. doi: 10.2174/157016308783769432.

Abstract

Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of anti-apoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as X-linked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Humans
  • Inhibitor of Apoptosis Proteins / pharmacology*
  • Inhibitor of Apoptosis Proteins / therapeutic use*
  • Monocytes / drug effects
  • Monocytes / immunology
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / pathology
  • Myelin Sheath / immunology
  • Myelin Sheath / metabolism
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Inhibitor of Apoptosis Proteins